Interview with André Choulika, President, France Biotech
France is a major pharmaceutical market, leader in Europe and number three in the world but it seems in biotechnologies, France lags behind. In your opinion, what has caused this?…
Genfit is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology.
Conscious of the importance of strategically aligning our company with patient needs, our R&D efforts are focused on contributing to bringing new medicines to market for patients with serious diseases whose treatment options are limited or non-existent.Our rigorous drug discovery and development process, and our commitment to improving health through innovation, have resulted in the creation of a pipeline dedicated to areas where we can lead and make a significant impact.
Our lead pipeline product Elafibranor (GFT505) has recently completed a positive Phase 2b study in NASH (Non-Alcoholic Steato-Hepatitis) and is currently launching a Phase 3 study. This metabolism-related liver disease, which can progress to cirrhosis and even liver cancer, shows a dramatically increasing prevalence worldwide. Elafibranor represents a major hope for patients and their physicians, who currently have no efficient treatment for NASH.
In addition to Elafibranor, our R&D pipeline relies mainly on our world-renowned scientific expertise in gene regulation and nuclear receptors.
It is comprised of multiple drug candidate research programs targeting novel mechanisms of action including the inhibition of RORγ-t.
GENFIT Headquarters
Parc Eurasanté
885, Avenue Eugène Avinée
59120 Loos
France
+33 (0)3 20 16 40 00
France is a major pharmaceutical market, leader in Europe and number three in the world but it seems in biotechnologies, France lags behind. In your opinion, what has caused this?…
After spending 15 years at the CEA (Nuclear Energy Center), you just accepted an offer to become the General Manager of INSERM at the very moment a political reform is…
July 2008 libre acèss (free access,) for OTC market was implemented – a measure where some selected OTC products were made available over the counter within the pharmacy. Could you…
The creation of AFSSAPS in 1999 was a milestone for the industry as it became the organism which gives authorization to enter a drug into the market. Can you explain…
The US chooses to price its innovative drugs based on a market approach which is very different from the French system. Could you explain how the French model rewards innovative…
What was the idea behind the creation of the « Etats Generaux de l’industrie » (General States of Industries)? What can we expect from them? The main idea is that…
See our Cookie Privacy Policy Here
